PACIFIC-AF
Randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to a NOAC (apixaban) in patients with atrial fibrillation (AF)
- Stage
- klaar
- Medicine
- Oral FXIa inhibitor BAY 2433334
- Population
- Ritme
- Phase
- II
- First Patient In
- 24 June 2020
- Last Patient In
- 21 June 2021
- Last Patient Last Visit
- 20 August 2021
Study Director
